News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biomet 3i Announces Enrollment in Its SternaLock® Blu Clinical Trial


2/13/2013 10:57:15 AM

WARSAW, Ind.--(BUSINESS WIRE)--Biomet, Inc., a global leader in the manufacture of orthopedic and biotechnology products, announced today that enrollment in the Company’s SternaLock® Blu clinical trial has begun. The SternaLock® Blu clinical trial is a prospective, randomized, controlled, multicenter trial that will compare patients whose sternum is closed with conventional wire cerclage to patients whose sternum is closed with Biomet’s SternaLock® Blu Primary Closure System to evaluate sternal bone healing following a full median sternotomy. Additional outcomes on post-operative pain and analgesic usage, patient function and quality of life, and complications will also be collected. The study will also compare the economic costs between the two groups.

Read at BioSpace.com

comments powered by Disqus
Biomet 3i
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES